Tumor-associated antigen presentation by dendritic cell

Tumor-associated antigen presentation by dendritic cell refers to the process by which dendritic cells (DCs), the most potent antigen-presenting cells in the immune system, acquire, process, and present antigens derived from tumor cells to T lymphocytes[1][3][5][8]. This process is essential for the initiation of adaptive anti-tumor immune responses, particularly the activation of cytotoxic CD8+ T cells via cross-presentation on MHC class I molecules, as well as the activation of CD4+ helper T cells via MHC class II[1][2][3][8]. The ability of DCs to stimulate tumor-specific T cells is a critical determinant of effective immunosurveillance and response to cancer immunotherapy, but can be hampered in the tumor microenvironment by immunosuppressive factors that render DCs dysfunctional or tolerogenic[3][9]. Tumor antigen cross-presentation encompasses a range of mechanisms and is influenced by DC subset, tissue localization, maturation state, and local signaling cues[1][2][3][4]. Key context: This is not a specific molecular target suitable for drug or antibody targeting; rather, it is an immunological process or pathway[1][3][5]. For structured data collection, the appropriate targets would be the individual molecules involved (such as MHC class I and II molecules, specific co-stimulatory molecules on dendritic cells, or the tumor antigens themselves), rather than the process of presentation[2][6][8]. Summary: "Tumor-associated antigen presentation by dendritic cell" should not be treated as a canonical molecular target; it is a process central to cancer immunology and immunotherapy research but not a druggable entity[1][3][5].

Other names

Cross-presentation of tumor antigens by dendritic cellTumor antigen presentation by dendritic cellAntigen cross-presentation